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Surgery during the 
COVID-19 pandemic
The COVIDSurg Collaborative1 
highlights a concerningly high 
rate of postoperative pulmonary 
complications and high mortality 
in a large cohort of perioperative 
patients with known or highly 
suspected severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
infection. Male patients at high risk 
(American Society of Anesthesiologists 
grades 3–5) and those patients 
undergoing emergency or major 
surgery fared the worst in terms of 
30-day mortality. Cancer surgery was 
also linked to elevated mortality, 
although non-urgent procedures 
might have been postponed during 
the first COVID-19 pandemic peak, 
which could have altered the patient 
mix. The absence of a control group 
is understandable given the need for 
efficient reporting, but nonetheless, it 
limited our understanding of the data.
Looking forward to a post-pandemic 
world, COVID-19 will have become a 
part of past medical history for many 
patients. Some patients, especially 
those with acute respiratory distress 
syndrome (ARDS), will have received 
critical care and might be living with 
severe consequences of COVID-19, 
requiring long-term rehabilitation. 
These patients might no longer be 
infected by SARS-CoV-2, but their lives 
will still be affected by the virus. The 
impact that this pandemic will have on 
perioperative and postoperative risk 
remains unknown.
Long-term analyses of ARDS 
related to the severe acute respiratory 
syndrome coronavirus outbreak in 
early 2000, and the H1N1 influenza 
A outbreak in 2009, showed that 
individuals with ARDS who have 
lived through these outbreaks had 
impaired pulmonary function, with 
worse spirometry, diffusion capac-
ity, functional performance, and 
radiographic appearance compared 
with matched controls.2–4 Historical 
cohort studies of all-cause ARDS 
also described a sustained impaired 
pulmonary function in these indi-
viduals.5
The COVIDSurg Collabo rative clearly 
show that surgery during acute 
SARS-CoV-2 infection generates 
excess risk. However, the question of 
when, or whether, this risk normalises 
again remains unclear. Answering this 
question will be key for safe planning 
of elective and emergency surgery in 
individuals who have had SARS-CoV-2 
infection.
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